AI Spotlight on LMAT
Company Description
LeMaitre Vascular, Inc.designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.
The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin.In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries.Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures.
It markets its products through a direct sales force and distributors.The company was formerly known as Vascutech, Inc.and changed its name to LeMaitre Vascular, Inc.
in April 2001.LeMaitre Vascular, Inc.was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Market Data
Last Price | 96.93 |
Change Percentage | -3.22% |
Open | 99.75 |
Previous Close | 100.15 |
Market Cap ( Millions) | 2179 |
Volume | 183295 |
Year High | 109.58 |
Year Low | 57.55 |
M A 50 | 98.34 |
M A 200 | 87.37 |
Financial Ratios
FCF Yield | 1.54% |
Dividend Yield | 0.66% |
ROE | 13.15% |
Debt / Equity | 5.54% |
Net Debt / EBIDTA | -4.43% |
Price To Book | 6.58 |
Price Earnings Ratio | 52.73 |
Price To FCF | 65.07 |
Price To sales | 10.23 |
EV / EBITDA | 36.07 |
News
- Jan -27 - LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
- Jan -27 - The Most Underrated Mistake Destroying Your Retirement - December Dividend Income Report
- Dec -24 - 4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
- Dec -16 - LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering
- Nov -26 - RMD vs. LMAT: Which Stock Is the Better Value Option?
- Nov -25 - LeMaitre to Participate at Upcoming Investor Conferences in December
- Nov -03 - LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
- Nov -01 - LeMaitre to Participate at Upcoming Investor Conferences in November
- Oct -31 - LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
- Oct -31 - LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
- Oct -31 - LeMaitre Q3 2024 Financial Results
- Oct -18 - BAX or LMAT: Which Is the Better Value Stock Right Now?
- Oct -15 - LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024
- Oct -02 - BAX vs. LMAT: Which Stock Is the Better Value Option?
- Aug -27 - LeMaitre to Participate at Upcoming Investor Conferences in September
- Aug -06 - Best Momentum Stock to Buy for August 6th
- Aug -02 - LeMaitre Vascular, Inc. (LMAT) Q2 2024 Earnings Call Transcript
- Aug -01 - LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
- Aug -01 - LeMaitre Q2 2024 Financial Results
- Jul -23 - LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Business Breakdown
Expected Mid-Term Growth
Segment nΒ°1 -> Medical Devices and Human Tissue Cryopreservation
Expected Growth : 8 %
What the company do ?
LeMaitre Vascular's Medical Devices and Human Tissue Cryopreservation segment offers vascular grafts and cryopreserved vascular tissues for surgical implantation.
Why we expect these perspectives ?
LeMaitre Vascular's 8% growth in Medical Devices and Human Tissue Cryopreservation is driven by increasing demand for vascular surgeries, advancements in cryopreservation technology, and expanding applications in regenerative medicine. Additionally, growing awareness of tissue banking and increasing adoption of minimally invasive procedures contribute to the segment's growth.
Lemaitre Vascular, Inc. Products
Product Range | What is it ? |
---|---|
XenoSure | A biologically active, sterilized, and decellularized arterial graft used for vascular reconstruction and bypass procedures. |
PROCOL | A vascular graft used for peripheral bypass procedures, featuring a collagen-impregnated Dacron graft. |
AlboGraft | A decellularized, non-synthetic vascular graft used for vascular reconstruction and bypass procedures. |
Xenograft | A sterilized, decellularized, and non-synthetic vascular graft used for vascular reconstruction and bypass procedures. |
Valvulotome | A surgical instrument used to excise and remove diseased or damaged heart valves. |
LeMaitre aortic punch | A surgical instrument used to create a circular hole in the aorta during cardiac surgeries. |
LeMaitre Vascular, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for LeMaitre Vascular, Inc. is medium due to the presence of alternative medical devices and procedures that can replace the company's products.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of LeMaitre Vascular, Inc.'s products and the lack of price sensitivity among healthcare providers.
Bargaining Power Of Suppliers
The bargaining power of suppliers is medium due to the presence of multiple suppliers for raw materials and components, but the company's dependence on a few key suppliers for critical components.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the medical device industry, including regulatory hurdles and the need for significant investments in research and development.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of several established competitors in the medical device industry, leading to a highly competitive market.
Capital Structure
Value | |
---|---|
Debt Weight | 6.02% |
Debt Cost | 3.95% |
Equity Weight | 93.98% |
Equity Cost | 8.35% |
WACC | 8.09% |
Leverage | 6.41% |
LeMaitre Vascular, Inc. : Quality Control
LeMaitre Vascular, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
Company | Rational |
---|---|
NEPH | Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and β¦ |
PDEX | Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that β¦ |
WRBY | Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and β¦ |
UTMD | Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD β¦ |
DXR | Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to β¦ |